Applied Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases by utilizing targeted drug development that leverages biomarkers and established clinical endpoints. Their approach addresses the urgent need for effective therapies in conditions with high unmet medical needs, such as Classic Galactosemia.
Funding
Funding not disclosed
Founders
Product
Problem
Many rare diseases lack effective treatments, leaving patients with limited or no therapeutic options to address their conditions. The development of new therapies for these diseases is often hindered by the complexity of the underlying biology and the challenges of conducting clinical trials in small patient populations. This results in a significant unmet medical need for individuals and families affected by rare genetic disorders.
Solution
Applied Therapeutics is a biopharmaceutical company focused on developing targeted therapies for rare diseases with high unmet medical need. The company leverages advances in molecular biology, biomarker identification, and clinical endpoint development to accelerate the drug development process. Their approach involves identifying molecules and pathways with established roles in disease biology and utilizing FDA guidance for biomarker use to bring products to market more efficiently. Applied Therapeutics aims to create transformative treatments that address the underlying causes of rare diseases and improve patient outcomes.
Target Audience
The primary target audience includes patients and caregivers affected by rare diseases, as well as healthcare professionals specializing in the treatment of these conditions.
Features
- Focus on rare diseases with significant unmet medical needs.
- Targeted drug development approach leveraging biomarkers and established clinical endpoints.
- Pipeline includes Govorestat for Classic Galactosemia and AT-001.
- Aims to accelerate the time from clinical development to approval.